Outside Source
Twenty-time UFC veteran C.B. Dollaway has been hit with a two-year USADA suspension after testing positive for multiple banned substances.
The anti-doping organization announced the sanction on Monday. Despite multiple infractions, Dollaway’s case is being treated as a single violation. The USADA statement is as follows:
Dollaway, 35, tested positive for anastrozole, growth hormone releasing peptide 2 (GHRP-2 or pralmorelin), a metabolite of GHRP-2, and GHRP-6 as the result of an out-of-competition urine sample he provided on December 19, 2018. Anastrozole is a Specified Substance in the class of Hormone and Metabolic Modulators, while GHRP-2 and GHRP-6 are Specified Substances in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics. All of these substances are prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency (WADA) Prohibited List.
Dollaway also tested positive for clomiphene in an out-of-competition urine sample collected on February 9, 2019. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy.
Additionally, Dollaway received an over-the-limit intravenous (IV) infusion on December 13, 2018. IV infusions and/or injections of more than 100 mL per 12-hour period are prohibited, except for those legitimately received in the course of hospital treatments, surgical procedures, or clinical diagnostic investigations.
Dollaway’s two positive tests and use of an over-the-limit IV were treated as a single, first violation because, after a thorough investigation, it was determined that the positive tests were consistent with ingestion prior to January 11, 2019, the date he received notification of his first positive test. Dollaway’s two-year period of ineligibility began on December 13, 2018.
Dollaway last appeared at UFC Fight Night 136 in Moscow on Sept. 15, 2018, when he suffered a second-round TKO defeat to Khalid Murtazaliev. That halted a two-bout winning streak for the Power MMA team representative, who was coming off back-to-back wins over Hector Lombard and Ed Herman. “The Doberman” is 11-9 over the course of his Octagon tenure.
Dollaway released a statement on his failed tests via Instagram.
In light of the recent decision made by USADA to issue me a two year sanction, I want it to be very clear that I did not knowingly nor intentionally take any performance enhancing drugs,” Dollaway wrote. “As many people close to me are aware, I suffered a serious back injury in 2016. With my insurance capped out, I needed to find alternative solution if I wanted to continue to compete in mixed martial arts.
“I traveled to Mexico to have a stem cell procedure done and ended up coming into contact with the mentioned substances. I am sorry to let my friends, family and fans down. I want to personally thank Donna Marcolini, the VP of health and performance of the UFC, for her assistance and for believing in me. I will take this time to continue working on my health and hopefully be ready to come back in 2020 as a healthy athlete/fighter for the first time since 2016.”
Dollaway injured his back in an elevator accident prior to UFC 203 in September 2016. As a result of the injuries suffered during that incident, his fight against Francimar Barroso was canceled.
This article first appeared at Recent News on Sherdog.com
Help support MMACrazies.com when you shop Amazon by starting your online Amazon shopping at MMACrazies.com/recommends/amazon. You are not charged extra, but we receive a small and very helpful commission on everything you purchase. Thanks for thinking of us every time you shop at Amazon.
